镭-223对骨转移去势抵抗性前列腺癌骨显像与生化标志物的影响:KYUCOG-1901研究
KYUCOG-1901前瞻性多中心研究纳入接受最多6周期镭-223治疗的日本mCRPC骨转移男性,纵向评估骨扫描指数(BSI)、血清骨代谢标志物(BMMs)和骨密度。结果显示BSI保持稳定,基线高BSI预测早期停药和较短rPFS,BSI升高与更差rPFS相关;BAP在伴或不伴骨改良药物(BMAs)患者中均短暂下降,TRACP-5b仅在接受BMAs者中下降;腰椎BMD轻度升高而股骨BMD不变。
要点
- 基线高BSI预测早期停药和较短rPFS,BSI升高与更差rPFS相关
- BAP在伴或不伴BMAs患者中均短暂下降,TRACP-5b仅在接受BMAs者中下降
- 腰椎BMD在伴或不伴BMAs患者中1年内均轻度升高,股骨BMD保持不变
核心结论
- 镭-223可稳定骨转移瘤负荷、短暂抑制血清骨代谢标志物并改善腰椎骨密度。
- BSI和血清BMMs提供预后信息,支持将其整合进纵向监测。
- 研究结果提示镭-223联合骨改良药物可能优化治疗结局。
研究设计与样本
- KYUCOG-1901为前瞻性多中心研究,纳入日本mCRPC伴骨转移男性,接受最多6周期镭-223治疗。
- 从基线至1年连续评估骨扫描指数(BSI)、血清骨代谢标志物(BAP、P1NP、TRACP-5b)和骨密度(BMD)。
- 通过BSI和血清BMMs评估影像学无进展生存(rPFS)、至症状性骨骼事件时间和总生存等临床结局。
主要发现
- BSI在整个治疗和随访期间保持稳定。
- 基线高BSI预测早期停药和较短rPFS,BSI升高与更差rPFS相关。
- BAP在伴或不伴BMAs治疗的患者中均出现短暂下降,TRACP-5b在接受BMAs的患者中下降。
- 基线BAP升高、治疗结束时BMMs升高以及治疗期间P1NP升高与rPFS相关。
- 腰椎BMD在伴或不伴BMAs患者中1年内均轻度升高,股骨BMD保持不变。
关键数值与推荐
- 基线高BSI预测早期停药和较短rPFS,BSI升高与更差rPFS相关。
- 基线BAP升高、治疗结束时BMMs升高及治疗期间P1NP升高与rPFS相关。
- BAP在伴或不伴BMAs患者中均短暂下降,TRACP-5b仅在接受BMAs者中下降。
- 腰椎BMD在伴或不伴BMAs患者中1年内均轻度升高,股骨BMD保持不变。
临床怎么用
- 可将BSI和血清BMMs纳入mCRPC骨转移患者镭-223治疗期间的纵向监测以获取预后信息。
- 基线BSI较高者可能需关注早期停药风险及更短rPFS。
- 镭-223联合骨改良药物可能优化治疗结局,但需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radium-223 dichloride (Ra-223) improves survival in men with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases, but its interaction with bone-modifying agents remains unclear. METHODS: The KYUCOG-1901 prospective multicenter study enrolled Japanese men with mCRPC and bone metastases treated with up to six cycles of Ra-223. Serial assessments included bone scan index (BSI), serum bone metabolic markers (BMMs; BAP, P1NP, and TRACP-5b), and bone mineral density (BMD) from baseline (BL) through one year. Clinical outcomes including radiographic progression-free survival (rPFS), time to symptomatic skeletal event and overall survival were assessed by BSI and serum BMMs. RESULTS: BSI remained stable throughout treatment and follow-up. High BL BSI predicted early discontinuation and shorter rPFS, and increases in BSI correlated with worse rPFS. BAP exhibited a transient decline in patients treated with and without bone-modifying agents (BMAs), while TRACP-5b declined in those receiving BMAs. Elevated BAP at BL and BMMs at end of treatment, and increases in P1NP during therapy, were associated with rPFS. Lumbar spine BMD increased modestly over 1 year in both patients treated with and without BMAs, while femoral BMD remained unchanged. CONCLUSION: Ra-223 stabilized skeletal tumor burden, transiently suppressed serum BMMs, and improved lumbar BMD in men with mCRPC. BSI and serum BMMs provided prognostic information, supporting their integration into longitudinal monitoring. These findings highlight the potential of combining Ra-223 with bone-modifying agents to optimize outcomes.
引用
- Shiota M, Enokida H, Murakami Y, et al. Impact of radium-223 on bone imaging and biochemical markers with and without bone-modifying agents in bone-metastatic castration-resistant prostate cancer: results from the kyucog-1901 study. Eur J Nucl Med Mol Imaging. 2026. PMID: 41665676. doi:10.1007/s00259-026-07807-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。